An observational study in Schizophrenia and Micrognathia, sponsored by Dalian Seventh People's Hospital. Status unknown at 1 site in China. Open to participants aged 17 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-30.
Sponsored by Dalian Seventh People's Hospital · Observational
This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.
The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR).
The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least.
This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.
the first-onset schizophrenia patients or drug-free suffers in the last 3 months，who are Chinese of Han descent and admitted to the Dalian Seventh People's Hospital,China
Exclusion Criteria:
15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT. The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated.
Drug: Atypical Antipsychotic · Other: atypical antipsychotic combined with MECT
15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
Also known as: olanzapine, quetiapine , ziprasidone and risperidone
The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
Also known as: MECT means modified electric convulsive therapy
the Baseline expression profiling of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia and the healthy controls at the beginning recruit for the microRNA-30e detection
Time frame: before the treatment
the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia at the 4-week treatment for the microRNA-30e detection
Time frame: Change from Baseline expression level at 4-week treatment
the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia at the 8-week treatment for the microRNA-30e detection
Time frame: Change from Baseline expression level at 8-week treatment
the scores of Positive and Negative Syndrome Scale(PANSS) for the patients with schizophrenia
The PANSS for estimating the severity of positive and negative symptoms in schizophrenia
Time frame: before, after 4 weeks and 8 weeks treatment
The degree of Personal and Social Performance scale(PSP) for the patients with schizophrenia
The degree of Personal and Social Performance scale(PSP) used to evaluate the disable levels in Multiple dimensions ,especially in social and self-care performance
Time frame: before, after 4 weeks and 8 weeks treatment
The scale of Clinical Global Impression(CGI) in patients with schizophrenia after treatment
Main purpose to provide a global rating of illness severity ,improvement and response to treatment for the patients with schizophrenia
Time frame: 4 weeks and 8 weeks treatment
Plan to share: Yes
This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.